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Lymphoid cells may be fractionated according to various properties. Macrophages 
may be removed by  their adhesive properties or  by allowing them  to  ingest iron 
powder and removing them by magnetism (1, 2). The remaining  population of lympho- 
cytes consists of the bone marrow-derived, bursa equivalent-processed B lymphocytes 
and the thymus-processed T  lymphocytes. The B cells have a high concentration of 
surface  immunoglobulin (Ig),  which  is  available for  detection by anti-Ig reagents 
(3-5), and provide the precursors of antibody-secreting cells (6). The T  cells, on the 
other hand,  have little if any surface Ig that  is available for  detection by anti-Ig 
reagents (3-5). T cells can be distinguished ant[genitally by the presence of the theta 
(4) or more genera[ thymus-specific antigens (7). Thus, fractionations of lymphocytes 
into B  or  T  cell-deficient  subpopulations may  be  accomplished by  utilizing their 
surface antigenic characteristics. 
By examining the  subpopulations of  lymphocytes that are  active in cellular im- 
munity, it has been demonstrated that T  cells are the predominant  cytotoxic effector 
cells in anti-It-2 tests in one in vitro system (8, 9). Recently, however,  some evidence 
has been presented for heterogeneity in the cytotoxic effector  cells in anti-H-2 tests 
(10). The lymphocyte subpopulations that are active effector cells in vitro with speci- 
ficity for tumor-specific and/or virally determined antigens have only recently begun 
to be defined (l l). BALB/e mice injected with Moloney sarcoma virus (MSV) 1  produce 
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lymphocytes that are active against Moloney leukemia virus (MLV)  antigen-bearing 
target cells (12) when the lymphoid cells are taken from animals that have developed 
no palpable tumors and from animals in which tumors have regressed (13). Lympho- 
cytes from tumor-bearing animals, on the other hand,  have been found to be much 
less active against specific tumor target cells in this system as well as others (13-15). 
By using lymphocytes from animals 30  days  after MSV infection in which primary 
tumors  had regressed  8-10  days  before  testing,  we  demonstrated  that effector  cells 
that were active in reducing target cell numbers were excluded from the immune cell 
population by passage over anti-Ig-coated glass bead columns (11). Furthermore, the 
target  cell-reducing effects  were  increased by  rendering  the  population  deficient  of 
T  cells using anti-T serum in the presence of complement (11). The activity of these 
lymphocytes was specific for the MLV-determined tumor cell surface antigen (11-13). 
The purpose of the present investigation was to examine in vitro the subpopu- 
lations of lymphocytes active in specific tumor target cell reduction through the 
entire course of development and regression of primary MSV tumors in BALB/c 
mice  and  to  further  characterize  the non-T  cell  involved in  this specific anti- 
tumor  cell  activity. 
Materials and Methods 
Animals.--Adult  BALB/c mice of both sexes were used as a  source of immune and con- 
trol lymphocytes. Control animals were matched with those that were MSV infected by sex 
and age in each experiment. 22 MSV-infected and 21 control animals were used in these ex- 
periments. 
Virus.--MSV-M (SVRP 224 prepared from the 224th passage in weanling BALB/c mice) 
was kindly provided by Dr. J. B. Moloney, National Cancer Institute, Bethesda, Md. 
Inoculations.--Animals  received  0.1  ml  of  the  MSV  suspension  intramuscularly in  the 
thigh, after which local  tumors developed  as  early as  5  days,  reaching peak  tumor size of 
10-15 mm about day 15, and usually completely regressing by days 20-25. Lymphocytes were 
harvested from MSV-infected animals every 5 days for 30  days. In one series of experiments 
the control animals received 0.1 ml of 0.25% sheep  red blood cells (SRBC) intraperitoneally 
at  the  time the matched experimental group  received MSV.  These animals were  tested at 
days 5 and 30. 
Medium.--Eagle's  minimal essential  medium  (MEM)  with  10%  heat-inactivated  fetal 
calf serum  (FCS),  100 U/ml penicillin, and 50 #g/ml streptomycin was used. 
Lymphocytes.  Axillary and inguinal lymph nodes and spleens, dissected out under sterile 
conditions, were pressed  through fine nylon  mesh into ice-cold  MEM  without FCS,  mixed 
with a  pasteur pipette, and passed over a  fine nylon mesh filter. The cells were pelleted by 
centrifugation and  resuspended  in  tris(hydroxymethyl)aminomethane-buffered 0.75%  am- 
monium chloride, pH  7.2,  and incubated for 10 rain at 37°C  to lyse erythrocytes (16).  The 
cells were washed three times in MEM without FCS,  resuspended in complete MEM,  and 
counted in a hemacytometer. 
Remo~'al of Macrophages (1, 2).~n  exp. no. 94 the non-T cell preparation was tested be- 
fore and after the removal of macrophages. Thereafter, (exps.  with numbers higher than 94) 
macrophages were removed before further fractionation was carried out. After the first wash, 
the lymphoid cell suspension, 2-4  X  l0 s cells  ill  5  ml of MEM,  was  mixed with carbonyl 
iron and incubated for 30 rain at 37°C with gentle agitation every 5 min. The iron was then 
extracted with the aid of a  magnet by passing the suspension through a  series of five sterile 
tubes, each time using the magnetic field to retain the iron in the discarded tube. The cells 
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this technique has been shown to decrease the percentage of macrophages in mouse peritoneal 
cells from 76  to  86~  down to  1% or less.  2 Analysis of the cells at  this point by immuno- 
fluorescence  using  rabbit  antimouse  and  goat  antirabbit  Ig  reagents  sequentially  showed 
25-35% of these cells to be surface Ig bearing. 
Preparation of Non-T Uelts.--Two methods were used to render the lymphocytes deficient 
of T  cells. The first method, using anti-T  serum in  the presence of complement, has been 
described previously  (11).  The second method  used  an anti-T  globulin  (ATG)  bound  to  a 
glass bead column to trap T  cells on the column. 
Anti-T Serum in the Presence of Complement.--By  using the anfisera with specificity for 
mouse T  cells it is possible to lyse these cells in the presence of complement leaving viable ceils 
that  are  predominantly B  cells  (7).  An anti-T  serum  produced in  a  rabbit against  mouse 
thymus cells and absorbed repeatedly with mouse myeloma cells and with spleen ce]ls from 
thymectomized, lethally irradiated,  bone marrow-protected animals has been described and 
characterized previously  (7,  9).  In the present experiments,  1-2  M  107 immune or  control 
cells were incubated in a  total volume of 0.5 ml with a  1 : 200 dilution of the anti-T serum for 
30 rain at 4°C, after which normal rabbit serum at a final concentration of 1 : 20 was added as a 
source of complement and incubated for 30 rain at 37°C. The mean cytotoxicity from all 20 
experiments for unfractionated spleen and lymph node cells by this antiserum was 48.0  4- 
14.3% for the immune cells and 44.7  4- 9.1% for the control cells. After determination of the 
viability by trypan blue exclusion, the cells were pelleted by centrifugation and resuspended 
in 0.25% trypsin in 0.01 M  phosphate-buffered saline, pH 7.4, without calcium or magnesium. 
After incubation for  10 rain at 37°C,  the trypsin was neutralized by the addition of MEM 
with FCS, and the suspension was passed over a  fine nylon mesh filter to remove aggregates 
of debris forming from  the  trypsinized dead  cells. The  cells were  then washed  twice with 
MEM  before use. This  procedure removes almost all  dead cells leaving a  95-100%  viable 
non-T cell population.  Appropriate dilutions of these cells were used for cytotoxicity tests. 
A sample of these cells was incubated overnight at 37°C in 5% COs in MEM without target 
cells to allow recovery of surface Ig from the trypsin treatment. These were then  analyzed 
in some experiments for the number of cells bearing surface Ig by immunofluorescence and 
found to be 85-95% surface Ig bearing. 
Preparation of Non-T Lymphocytes Using A TG Columns.--Glass beads with an average 
diameter of 200 #m  (Superbrite  100-5005;  Minnesota Mining and  Manufacturing  Co.,  St. 
Paul, Minn.) were cleaned by treatment with equal parts of sulfuric acid and nitric acid; then 
they were washed and boiled in distilled water. Sterile, filtered ammonium sulfate-precipitated 
globulin from normal rabbit serum (NRS)  was then added at a  concentration of 1-2 mg/ml 
of bead material, suspended in sterile saline. The beads were incubated overnight at  +4°C 
and then poured into 1.5  >(  30 cm columns with an approximate volume of 50 ml. A sterile, 
filtered sheep antirabbit Ig serum (Statens Bakteriologiska Laboratorium, Stockholm, Sweden) 
was then added to the columns at a  dilution of 1:2. The columns were allowed to stand for 1 
h at room temperature, were washed off with sterile saline, and filtered with a  1:2 dilution of 
a  rabbit  antimouse  thymus  serum  (ATS,  cytotoxlc titer  1:500,000).  After another  1  h  at 
room  temperature  the columns were washed with sterile saline and  ready for use.  Control 
columns were prepared in an identical manner to the ATG columns, except that in the last 
step NRS 1:2 was substituted for ATS  1:2. Although the ATS, prepared by repeated injec- 
tions of mouse thymus cells into rabbits over a  period of 8 mo, had not been adsorbed with 
B  ]ymphocytes, the ATG columns prepared with it showed a  marked capacity to remove T 
lymphocytes from mouse lymphocyte populations as shown by morphological and functional 
tests in Table I. In the present experiments 2-5  X  107 immune or control lymphocytes were 
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TABLE  I 
Functional  and  Morphological  Characteristics  of Mouse  Lymphocyles  Fractionated  by A TG or 
Anti-Ig Columns 
Lymphocytes passed 
through column with* 
GVH functions  Helper function 
B cells§  Depression of allogeneic  B cells  Antihapten responseLI  bone marrow 
%  %  % 
Unfractionated  31  56  --  -- 
NRG  19  64  38  18.5 
NMG  --  --  33  10.4 
ATG  82  24  90  1.6 
Anti-Ig  < 1  56  < 1  12.5 
No cells  --  --  --  0.5 
NRG,  normal  rabbit globulin;  NMG,  normal  mouse globulin;  ATG,  rabbit  anti-T  cell 
globulin. 
* Lymphocytes:  lymph  node  cells  from  normal  CBA  mice  for  GVH  (graft-vs.-host) 
function,  or  from  (CBA X  C57BL)F1  mice  immune to bovine  serum  albumin  (BSA)  for 
helper function. 
GVH  function:  5 X  10 ~  CBA  lymphocytes  were  injected  into  (CBA X  C57BL)F1 
mice that were previously irradiated with 700 R  and  given 2  X  106 syngeneic bone marrow 
cells. The  59~Fe uptake in spleens was determined 7 days later and expressed in relation to 
control animals receiving bone marrow cells only. 
§ %  B  cells:  percentage of cells with  membrane fuorescence using  a  conjugated  goat- 
antimouse Ig serum. 
I] Antihapten response: antigen-binding capacity in nanograms per milliliter of  serum in 
syngeneic mice  given  400  R  and  injected with  5  X  10 ~ fractionated  cells  together  with 
2  X  107  anti-NIP-OA cells and  10  #g  of NIP-BSA.  Each  value  is the mean from five to 
six animals determined 7 days after the cell transfer. 
placed on these ATG columns. The cells that passed through (about 30-40% recovery) were 
used for cytotoxicity tests. Analysis of these preparations by immunofluorescenee showed the 
passed cells to be 85-95% surface Ig bearing. 
Preparation  of T Cells.--By filtering lymphocytes through glass bead columns, coated first 
with mouse Ig and then with rabbit antimouse Ig in excess, it is possible to trap cells with a 
high concentration of membrane-bound Ig, i.e., B  cells. Thus, the passed populations will be 
primarily T  cells (7). Lymphocytes eluted from such columns have been demonstrated to be 
predominantly T  cells by multiple criteria  (7,  9).  In  the H-2 system, immune cells eluted 
from such a  column have an increased cytotoxicity against the appropriate target  cells  (9). 
In two other systems, including the present one using regressor mice (11)  and a system using 
chicken erythrocytes coated with soluble antigens as  targets  (17,  18),  specific effector cells 
were retained by passage through these columns. 2-5  X  107 lymphocytes from immune or 
control animals were fractionated by use of these anti-Ig columns as previously described (7). 
After passage  the cells were centrifuged,  resuspended in  MEM,  and  appropriate  dilutions 
were used for  cytotoxicity tests. In some experiments samples were saved for analysis by 
immunofluorescence and anti-T serum sensitivity. The mean cytotoxicity of anti-T serum in 
the presence of complement (at  the same concentrations described in  the previous section) 
was 81.3  ±  11.2% for the immune cells and 81.1  4- 9.6% for the control cells. The number 
of cells bearing surface Ig as detectable by immunofluorescence was reduced to 2-5%. 
Target  Cells.--The  following cell lines were used:  (a) Ha2  cells: a  line  established from 1476  B  AND  T  CELL  RESPONSE  TO  MSV  TUMORS 
an MSV-induced  tumor of a  CBA mouse.  These cells produce infectious virus, possess the 
MLV-determined cell  surface antigen  (19),  and have been shown to  be sensitive to  MSV- 
immune lymphocytes in microcytotoxicity tests (11-13) but not to lymphocytes immune to 
a nonpertinent antigen (11,  13). (b) D56 cells: a mixture of S+L  -  (sarcoma positive, leukemia 
negative) cells and normal 3T3  cells from NIH  Swiss  embryo fibroblast cultures. The cells 
contain the MSV genome but do not produce any infectious virus nor do they possess a viral- 
associated surface antigen that would distinguish them from normal 3T3 cells (12), and they 
are not sensitive to MSV-immune lymphocytes (11-13). (c) D56-M cells: MLV-superinfected 
D56  cells.  These  cells  produce  infectious  virus,  possess  the  MLV-determined  cell  surface 
antigen, and are sensitive to MSV-immune lymphocytes in microcytotoxicity tests (11-13). 
(d) D245-B-3-M:  this line,  now superinfected with MLV,  was originally designated D245- 
B-3  an  S+L  -  line  that  was isolated by appropriate selection procedures from  MSV-trans- 
formed BALB/c 3T3 cells (20). The superinfected line produces infectious virus and possesses 
the  MLV-determined  cell  surface  antigen. '3  (Cell  lines  D56  and  D245-B-3  were  provided 
through the courtesy  of Dr.  R.  H.  Bassin,  National Institutes of Health,  Bethesda,  Md.) 
Determination  of  Lymphocyte  Cylotoxicily.  The  microcytotoxicity  method  of  Takasugi 
and Klein (21)  was used with the following modifications: 50-400  target cells  were  seeded 
into each well of microplates  (no.  3034; Falcon Plastics,  Div.  of BioQuest,  Oxnard,  Calif.) 
and incubated overnight at 37°C  in 5% CO.~. Lymphocytes were added to the target cells in 
concentrations of 10,000,  5,000,  2,500 and 1,250 per well in 10 ~1 of MEM.  In some experi- 
ments the highest concentration was 5,000 and the lowest 625.  Control and immune lympho- 
cytes of each fraction were always tested on the same plate using six replicates for each lympho- 
cyte dilution and 6 or 12 replicate wells containing no lymphocytes (blank control). After in- 
cubation for 40-48 h, medium was removed and the plates were washed once with balanced 
salt solution to remove dead cells.  The plates were fixed and stained, and the target cells re- 
maining in each well or a  representative portion thereof were counted (hereafter reference to 
well indicates the number of target cells  remaining in the well).  The log mean and standard 
deviation (SD)  of the six replicate wells was determined and a  Student's t test was performed 
to assess  the significance of the differences between wells containing immune lymphocytes 
and those containing the same number of control lymphocytes.  A  significant difference be- 
tween control and immune wells was considered to exist when the P  value was less than 0.05. 
The relative percentage of remaining target cells in wells  containing immune lymphocytes 
was  calculated  compared  with  wells  containing  the  same  number of  control lymphocytes 
using  the geometric mean of  the six  replicate wells  for each  lymphocyte dilution.  Control 
]ymphocytes from 21 animals and immune lymphocytes from 22 animals and their fractionated 
subpopulations were tested in 20 separate experiments on days 5,  10, 15, 20, 25, and 30 after 
MSV infection. 
EVALUATION  OF  RESULTS 
Because the microcytotoxicity test encompasses several parameters including 
cytotoxicity,  inhibition of  target  cell  growth,  target  cell  detachment  without 
killing, and even stimulation of target cell growth,  the evaluation of the results 
requires special attention. 
We have chosen geometric calculations rather than arithmetic to compare the 
number  of  target  cells surviving in  wells  with immune  lymphocytes  and wells 
with  the  same  number  of  control  lymphocytes,  because  the  test  is  clearly  in- 
fluenced  by  exponential  cell  growth.  By  counting  the  number  of  cells  in  the 
3 E. M. Feny6, personal communication. LAMON,  WIGZELL,  KLEIN,  ANDERSSON~  AND  SKURZAK  1477 
blank controls using two different target cell concentrations that were stopped 
at 16 and 48 h or 24 and 48 h, we calculated the doubling time of the Ha2 target 
cell.  Using the mean target cell number from 12-18 samples for each value, we 
found the mean doubling time to be 10.3 h by the formula: 
g  =  t(ln2)/ln(C2/C1),  where g  =  doubling time, t  =  time interval (t2 --  tl), C1  =  cell num- 
ber at tl, C2  =  cell number at t2. 
We selected the absolute number of lymphocytes per well as the parameter 
for comparison rather than the lymphocyte to target cell ratio for two reasons: 
First, since the target cells are growing during the test, the ratio does not remain 
constant. Second, in pilot experiments testing from 40,000 to 312 lymphocytes 
on 50-200  target cells,  we found  that no  specific effects of the  immune  cells 
could  be  distinguished  when  using  more  than  10,000  lymphocytes per  well 
(106/ml in a vol of 10/zl). The effects of the normal lymphocytes at these higher 
concentrations were as great or greater than the immune lymphocytes. This was 
true regardless of the target cell number. Thus, for these experiments we chose 
titrations of lymphocytes from 10,000  down to 625 lymphocytes per well. 
For unknown reasons, clear titration effects were not seen in most instances 
using graded lymphocyte numbers. We thus evaluated our results on the  basis 
of statistical significance between immune and control wells rather than  using 
the relative percentage of remaining target cells.  In order to be able to compare 
the activity of an animal's lymphocytes in a single figure, a cytotoxic rating  is 
shown, based on significant target cell reduction (P <  0.05) found in zero dilu- 
tions --, in one dilution +, two dilutions -{- +, three dilutions -{--t--{-, and four 
dilutions +  +-t-+.  This cytotoxic rating is based on the significant  reduction 
of the target cell numbers as compared with wells with the same number of con- 
trol lymphocytes. Occasionally there was significant stimulation of cell growth 
by the immune lymphocytes. These instances are indicated in the results. 
Finally, in some cases (4 out of 21 experiments with the unfractionated cells) 
the normal control lymphocytes were significantly cytotoxic to the target cells 
when compared with the blank control. However, when comparing the percent- 
age of surviving target cells in wells with control lymphocytes and the blank 
controls from all experiments, the mean survival of the target cells was 106% 
of the number of cells in  the blank.  This value was the same for the unfrac- 
tionated and both T  and non-T fractions. In view of this, one might consider 
comparing the effects of the immune cells to the blank control only. This ap- 
proach has some merit since the "normal" lymphocytes in a  small number of 
cases might not be normal because of room infection of these normal animals 
with C-type viruses. However, the reduction of the number of target cells by the 
immune lymphocytes compared with normal control lymphocytes is kept as one 
of our main criteria for specificity. We feel that the need for rigorous specificity 
controls far outweighs the risk of having a few negative results because of cyto- 
toxicity from the  control  lymphocytes (in  fact,  the  overall  pattern  was not 1478  B  AND  T  CELL  RESPONSE  TO  MSV  TUMORS 
changed  by  these  instances  of  cytotoxicity  from  the  control  lymphocytes). 
Furthermore, there are a number of unknown factors involved, which may differ 
from test to test, such as promotion of target cell growth by medium condition- 
ing or by cell-to-cell contact from the added lymphocytes, as well as inhibition 
of target cell growth by competition for nutrients and accumulation of metabolic 
wastes by the added lymphocytes. Thus,  to ensure that conditions in immune 
and control wells are as nearly alike as possible including these unknown factors, 
the only valid comparison is with wells that have the same number of target 
cells and the same number of immune or control effector cells. 
RESULTS 
Activity of the U~fractionaled Lymphocyles vs. MLV Antigen-Bearing  Target 
Cells.--Table lI shows the activity of the unfractionated lymphocytes vs. the 
three MLV antigen-bearing target cell lines. Experiments up to and including 
no. 94 were performed using spleen and lymph node cells from which the macro- 
phages had not been removed. Experiments with numbers higher than 94 were 
performed  using  lymphocytes  that  had  been  rendered  macrophage-deficient 
using carbonyl iron and magnetism. As previously reported in this system (13), 
the unfractionated lymphocytes from MSV-infected animals were found to be 
active in specific target cell reduction from animals that had not yet developed 
tumors at the time of testing and more predictably so, from animals in which 
tumors had completely regressed. Tumor-bearing animals, in general, were found 
to have the least active lymphocytes; two exceptions to this are seen in exps. 49 
and 104 at 10 and 20 days after MSV infection, respectively. The animals tested 
at 15 days at peak tumor size, however, were found invariably to have the least 
active lymphocytes. In exps. 110 and  111  the unfractionated cells were passed 
over control columns coated with normal rabbit globulin  (NRG). Active cells 
were not excluded by this procedure. 
T Cell Aclivity.--Table III shows the activity of the cells passed through anti- 
Ig columns vs. the MLV-positive cell lines. These cells show two distinct peaks 
of activity: just before tumor development on day 10 and just after regression 
on days 20 and 25. The T lymphocytes from the tumor-bearing animals on days 
5 and 20 were found to have a greater activity than the unfractionated cells on 
the same days. At peak tumor size, however, the T  cells were also inactive. By 
30 days after MSV infection, passage of the immune cell populations over the 
anti-Ig columns significantly reduced the inhibitory effects on the target cells in 
each experiment. In exp. 56 only the highest concentration of T  cells was found 
to produce significant reduction of the Ha2 target cells.  This was not found at 
lower concentrations.  In the other  two experiments at day 30,  significant in- 
hibitory  effects were  completely eliminated  by passing  the  cells over anti-Ig 
columns. 
Xon-T Cell Aclivity.--Table IV shows the activity of the non-T cells vs. MLV 
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prepared by both methods (a) by anti-T serum in the presence of complement 
and (b) by ATG columns. All the other non-T cell preparations were fractionated 
by method a only, except exp. 111 in which the cells were fractionated by method 
b only. In  exps.  108,  109,  and  110  the cells  prepared  by both methods were 
found to have identical activities against the target cells. In exps. 108 and 109 
both preparations were inactive. In exp. ll0 both preparations were found to 
significantly reduce the target cell numbers in the same three lymphocyte con- 
centrations and  the percentage of surviving  target cells  at each dilution was 
almost identical. 
In exp. 94 the non-T cells were tested before and after the removal of macro- 
phages with carbonyl iron (Table IV 94a and 94b, respectively). Removal of the 
macrophages clearly increased the inhibitory effects of the non-T cells.  In ex- 
periments  after  no.  94,  macrophages  were  removed from the  initial  unfrac- 
tionated cells before further fractionation. 
Activity is seen in this non-T cell subpopulation both before and after (but 
not during) peak tumor size; however, at 30 days the non-T cell fraction con- 
tinued to be active. In three of the four experiments at this time the activity 
was increased by rendering the lymphocyte population deficient of T  cells and 
in no case at day 30 was there any decrease in the activity by this treatment. 
Specificity.--This  lymphocyte-mediated target cell reduction has previously 
been shown to be specific for the MLV-determined cell surface antigen, by the 
unfractionated lymphocytes throughout the entire 30 day period (13)  and by 
the non-T cells from regressor animals 30 days after virus infection (11). Table V 
shows the effects of the T cell and non-T cell fractions at day 25 (exp. 55) on the 
I)56 cell line. No significant reduction is demonstrable by either fraction against 
this cell line that is S+L  -. Whereas, both these fractions in the same experiment 
were significantly cytotoxic to the D56-M cell line (Tables III and IV). These 
two  lines  are  identical  except for the production of infectious virus  and  the 
presence of the MLV-determined surface antigen on the latter. 
In one series of experiments the donors of control lymphocytes were immu- 
nized  against  SRBC  in  order  to  determine  whether  there was  a  differential 
activity by the  MSV-immune  lymphocytes compared with lymphocytes im- 
mune  to  a  nonpertinent antigen.  The unfractionated MSV-immune  lympho- 
cytes on day 30 (exp. 68, Table II), the T  cells on day 5 after MSV (exp. 64, 
Table III), and the non-T cells from an MSV regressor animal on day 30 (exp. 
68, Table IV) produced significant reductions of the number of target cells com- 
pared with the effects of SRBC-immune lymphocytes that were prepared in the 
same way. Thus, this lymphocyte-mediated reduction of target cells by either 
unfractionated, T cells, or non-T cells is specific by the following criteria: (a) The 
MSV-immune lymphocytes significantly reduce the number of surviving target 
cells (Ha2, D56, D56-M, and D245-B-3-M) compared with control lymphocytes 
from uninoculated animals.  (b)  The immune lymphocytes are  active  against 
only those target cells that possess the MLV-determined surface antigen but not 1480  B  AND  T  CELL  RESPONSE  TO  MSV  TUMORS 
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cells that are MLV antigen free. (c) The activity of the MSV-immune lympho- 
cytes is significant compared with the effects of SRBC-immune cells in the same 
experiments. 
The Time Required In Vitro for Significant Effects to Appear.--25 days after 
MSV infection in a regressor mouse when both T  and non-T cell fractions were 
found to be active, an  experiment was  performed to determine the  time re- 
quired in vitro using the microcytotoxicity test for each fraction, as well as the 
unfracfionated cells,  to show significant effects. The results of this experiment 
are shown in Table V1. Using the same target cell, we stopped the experiment 
at  16,  24,  and  48  h  after  adding  the  lymphocytes. Two  distinct  patterns 
emerged. While  the  T  cell fraction and  the  unfractionated lymphocytes re- 
quired 48  h  for the detection of significant reduction of target cell numbers, 
the non-T cells produced significant reduction as early as 16 h  and the effects 
were less detectable as the incubation time increased. 
DISCUSSION 
We have presented an analysis of the immune competence of lymphoid cells 
from BALB/c mice undergoing a primary outgrowth and regression of Moloney 
sarcoma virus-induced tumors to selectively inhibit the growth of MLV antigen- 
bearing target cells in vitro. We have attempted to demonstrate the relative 
roles of T  and non-T lymphocytes in the specific inhibition as affected by time 
after administration of MSV in vivo. 
In  order  to  selectively produce  "pure" T  lymphocytes, cells were filtered 
through  columns coated with  anti-lg,  known  to remove the  B  lymphocytes 
while leaving the T  lymphocytes in the passed population (7). Normally such 
anti-Ig columns will remove more than 90% of B  lymphocytes as judged by 
morphology and function (7), and correspondingly, according to surface antigens 
a  lymphocyte population consisting of more than 90% T  lymphocytes is ob- 
tained in the passed population (7). This passed population can be shown in vivo 
as well as in vitro to have the expected specific immune capacity of normally 
functioning T  lymphocytes (7), and there is no evidence that such cells have 
been damaged by the passage through the anti-Ig columns. If mouse anti-H-2- 
immune  cells are filtered through such  columns and subsequently tested for 
cytolytic activity in vitro against relevant, H-2-incompatible target cells,  there 
is normally an increase in the activity of the passed cells in comparison with the 
original population (9). 
Two different approaches were used to purify B  lymphocytes from a mixed 
population of lymphocytes. The first approach was using  selective lysis of T 
cells by anti-T serum plus complement, followed by trypsin treatment (to re- 
move dead cells and antigen-antibody complexes) and recovery at 37°C  (11). 
The other approach took advantage of a  column separation technique where 
triple layers of material provided a high concentration of anti-T cell antibodies 
in the outermost layer. Such columns can be shown to selectively deplete the 1488  13  AND  T  CELL  RESPONSE  TO  MSV  TUMORS 
passing  cells  of T  lymphocytes as judged  both  by morphology and function 
(present article and [22]). The two methods of preparing T  cell-deficient sub- 
populations produce cells  that are 85-95 %  surface Ig positive, and the MSV- 
immune non-T cells prepared by either method behave in an identical manner 
with respect to their target cell-reducing capacities. The possibility had previ- 
ously existed that immune cells fractionated using anti-T serum in the presence 
of complement could somehow be  activated  by the  antiserum,  complement, 
and/or trypsin and further washing. This was not very likely since the control 
lymphocytes were  treated  in  the  same  way  without  inducing  any  activity 
against the target cells (11). Also, the very same antiserum in the presence of 
complement completely abolished the ability of T  cells to be cytotoxic to target 
cells  in anti-H-2 tests  (9). Furthermore, the  MSV-immune lymphocytes pre- 
pared in this way were active against MLV antigen-bearing target cells but not 
against control target cells that were MLV antigen free (11). Finally the identi- 
cal behavior in microcytotoxicity tests of the cells prepared by ATG columns 
further validates the conclusion that the specific in vitro activity of these cells 
is  indeed  a  property of this fraction of immune  cells rather than  a  possible 
product of in vitro manipulations. 
All the lymphocyte fractions studied in this system were least active if taken 
from  tumor-bearing hosts  at  peak  tumor  size  (day  15).  Several possibilities 
exist that might explain this phenomenon. All the active lymphocytes might be 
aggregated at the tumor site (23)  or specific lymphocyte hyporeactivity could 
have been induced by antigen overload (24). One possibility, which seems par- 
ticularly compelling in this system, is that otherwise normal lymph node and 
spleen cells might in fact be antigenically converted by the virus to possess the 
MLV-associated surface antigen. It has already been demonstrated that viremic 
animals,  injected with MLV as neonates, have normally functioning lympho- 
cytes that are MLV antigen positive (25). Immunizing such animals with SRBC 
and treatment of the viremic animals' spleen cells with anti-MLV serum in the 
presence of complement reduces the number of plaque-forming cells;  whereas, 
the same treatment of the control SRBC-immune spleen cells has no effect (25). 
Large tumors in the MSV system are known to shed infectious virus (26). If, as 
a result of viremia, a significant percentage of the lymphocytes are MLV antigen 
positive in the tumor-bearing host, when lymphocytes are added to the target 
cells,  this  number  of  MLV  antigen-positive  lymphocytes could  conceivably 
mask any inhibitory effects of the simultaneously present immune lymphocytes. 
This possibility is currently under investigation in this laboratory. 
The T  cell activity in this system appeared to be related in time to have a 
peak just before tumor development and just after regression and in some cases 
when small tmnors were present. In two instances, with animals bearing tumors, 
the T  cell activity was greater than the corresponding unfractionated or non-T 
cell reactions in the same experiments. In none of these experiments with early 
or late tumor-bearing animals was there any decrease in specific antitarget cell LAMON,  WIGZELL,  KLEIN,  ANDERSSON, AND  SKLIRZAK  1489 
activity by passage of the cells over anti-Ig-coated columns. The T  cell activity 
in this system, thus, seems to be transient, fading rather rapidly after regression. 
The fact that T  cells are active in  this system is not surprising.  T  cells have 
been shown to be active cytotoxic effector cells in the transplantation systems 
where immunization has taken place across major histocompatibility barriers 
(8,  9). 
Non-T cells, on the other hand, have been reported to be active killer cells in 
antibody-coated target cell  systems (27,  28)  where there seems to be a general 
requirement for the addition of sensitizing antibody to the target cells (27-30). 
The cytotoxicity can  then  be affected by normal lymphoid cells (27-30)  and 
appears to be dependant  on Fc receptors present on the surface of the non-T 
cells (31). In recent reports in the present system (11)  and a nontumor system 
using soluble antigens bound to target cells (17,  18),  no extrinsic antibody was 
used; only sensitized lymphocytes were added to the target cells. In both these 
systems, passage of the immune cells over anti-Ig columns decreased their cyto- 
toxic or inhibitory effects on the target cells indicating a non-T effector cell. 
The non-T cells active in  this system could conceivably be some cell  other 
than a  B  cell.  However, there is increasing evidence in favor of B  cells being 
active as effector cells in this system. Active effector cells can be excluded at 
day 30 after virus infection on anti-Ig columns indicating a high concentration 
of surface Ig on the active cell at this time. Fc receptors on cells other than B 
cells (32,  33)  could be involved in the retention,  although,  as yet this has not 
been found with these columns (7). Also, the fact that neither ATG columns 
nor NRG columns inhibited specific antitarget cell  activity would tend to ex- 
clude this. The non-T cells prepared by ATG columns or anti-T serum in the 
presence of complement were 85-95 %  surface Ig positive. The 5-15 % of these 
preparations with no detectable surface Ig are unlikely to be the active effector 
cells,  since  significant  target cell reduction  has been observed with  as few as 
1,250  lymphocytes. This would mean that the active effector cell would have 
to be present in concentrations as low or lower than  the target cells,  and the 
number in  this population  that was committed to this specific antigen  would 
be even lower. We had previously reported that decreasing the percentage of 
macrophages from the non-T cell fraction by passage over a cotton wool column 
did not decrease the activity of this subpopulation of immune cells (11). In the 
present experiments, eliminating macrophages using carbonyl iron and magnet- 
ism, in fact, increased  the  activity against  the  target cells by the non-T cell 
fraction of immune cells compared with  the control lymphocytes treated  the 
same way. 
The time required in vitro for significant effects to appear with each fraction 
would seem to indicate  that the non-T cells in this sytem have a  more rapid 
mechanism of action compared with the T  cells.  48 h  incubation was required 
for observation of significant T  cell activity in this system, which is compatible 
with previous investigations using  the microcytotoxicity method for anti-H-2 1490  ~B  AND  "1"  CELL  RESPONSE  TO  MSV  TUMORS 
tests (22).  Antibody secreted by immune B  cells in this system might be ex- 
pected to have a quite rapid effect. 
The mechanism of reduction of target cell numbers by these cells is unknown. 
If B cells are indeed responsible for this specific activity of the immune non-T 
cells in this system, the binding of effector cell to target cell could take place 
by two different mechanisms. Antibody could be secreted by a  few immune 
cells that would bind to the target cells and bring about cytotoxicity through 
the receptor for antigen-antibody complexes on normal B cells (7, 34-36). Such 
a phenomenon has been demonstrated to exist in several systems (27-31)  in- 
cluding the MSV rat system where target cells pretreated with antisera were 
reduced in numbers by the lymph node cells (37). On the other hand, the specific 
immune B cells might be able to lyse the target cell directly by unknown mech- 
anisms after the membrane-bound Ig has established the killer to target contact 
(38). 
The cellular immune response to this primary viral tumor as measured in 
vitro by microcytotoxicity tests against MLV antigen-bearing target cells is a 
heterogenous one involving both T and non-T (probably B) lymphocytes. The 
T  cell response is most active close to tumor development and regression. The 
B cell activity also begins early after MSV infection, is depressed at peak tumor 
size (as is T cell activity), emerges again after regression, and remains high late 
in the immune response even as the T  cell activity tapers off. 
The  present  experiments have  raised  several  questions including whether 
non-T cell activity is a predominant feature of all tumor systems or is just a 
peculiarity of the present one. Preliminary evidence from this laboratory indi- 
cates that non-T cells are also active in specific in vitro target cell reduction in 
the methylcholanthrene-induced sarcoma system of mice. Also, evidence using 
tumor targets and lymphocytes from patients in a similar assay suggests non-T 
lymphocyte involvement.  4 
Finally, a note of caution should be added. There exists ample evidence that 
T  cells are capable of in vivo cytolytic activity against foreign cells (39, 40). It 
remains to be established if a  similar effect can be demonstrated by specific 
non-T cells or B cells, although preliminary support for such a mechanism exists 
(41). 
SUMMARY 
Adult BALB/c mice were injected with Moloney sarcoma virus (MSV) after 
which the animals' lymphocytes were examined/or activity against Moloney 
leukemia virus  (MLV)  antigen-bearing target cells  at 5-day intervals for 30 
days. Lymphocytes from these  animals and  appropriately matched controls 
were fractionated into B  cell-deficient (primarily T  cells)  and T  cell-deficient 
(primarily  ]3  cells)  subpopulations.  Macrophages  were  removed  using  iron 
40'Toole,  C., P. Perlmann, H. Wigzell, and B. Unsgaard. 1973.  Lymphocyte cytotoxiclty 
in bladder cancer. No requirement for thymus derived cells. Lancet. In press. LAMON, WIGZELL, KLEIN, ANDERSSON~ AND  SKURZAK  1491 
powder and magnetism. The unfractionated lymphocytes, T  cells,  and non-T 
cells were then tested in microcytotoxicity tests. Antigen-specific activity was 
found in  the unfractionated  lymphocytes from animals that had not yet de- 
veloped palpable tumors and from regressor animals. The T  cells were active 
just before tumor development and just after regression; however, by day 30 
after virus infection (8-10 days after regression) the T  cell subpopulation was 
much less active. The non-T cell subpopulation was also active before tumor 
development and soon after regression. However, this activity continued to rise 
after regression and was highest at 30 days. At day 15 (peak tumor size) neither 
subpopulation was active. The activity was demonstrated to be specific for the 
MLV-determined  cell  surface  antigen  by testing  on  control  target  cells  that 
were MLV antigen negative and by comparison of the inhibitory effects with 
lymphocytes immune to a nonpertinent antigen as well as normal lymphocytes. 
The non-T cells were tested for activity before and after removal of macrophages 
with iron powder and magnetism. Such cells were significantly more active after 
removal of the macrophages. These data demonstrate specific T  cell and non-T 
cell activity in microcytotoxicity tests with a tumor-specific system and strongly 
suggest that the non-T cell activity described herein is a B  cell function. 
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